2025
Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Feng D, Crowley F, Hapanowicz O, Venturini N, Lucas N, Wu K, Wilk J, Sadek N, Hamon P, Hennequin C, Devraj V, Thanigaimani P, Uldrick T, Miller E, Lowy I, Doroshow D, Tabrizian P, Schwartz M, Merad M, Marron T. Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e16320.Peer-Reviewed Original ResearchTreatment-related adverse eventsRelapse-free survivalOverall response rateAnti-PD-1Single-institution experienceResectable hepatocellular carcinomaNeoadjuvant immunotherapyHepatocellular carcinomaAdverse eventsTumor necrosisPathological responseSingle-agent anti-PD-1Early-stage hepatocellular carcinomaEarly-phase clinical trialsGrade 3 hepatitisAdvanced hepatocellular carcinomaDelay of surgerySurvival of patientsCombination immunotherapyNeoadjuvant settingAdjuvant immunotherapyResected tumorMetastatic diseaseImmunotherapy regimensNeoadjuvant nivolumab
2024
Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs Health Care SystemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosisShort-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Ibrahim S, Fortune B, Talenfeld A, Madoff D, Johnson M, Sedrakyan A. Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison. American Journal Of Roentgenology 2024, 223: e2431272. PMID: 38899842, DOI: 10.2214/ajr.24.31272.Peer-Reviewed Original ResearchEarly-stage hepatocellular carcinomaHepatocellular carcinomaPost-procedure periodIndex procedureOut-of-pocket costsPatient out-of-pocket costsDrivers of high costsDays post-procedureSubgroup of patientsTreated with ablationPropensity-matched subgroupsU.S. population-based studyPopulation-based studySurgical resectionMultivariate linear regression modelSurgical treatmentPrognostic indicatorPost-procedureTreatment modalitiesTreatment optionsSEER-MedicareResectionMultivariate analysisTransplantationPropensity-scorePartial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis
Wang J, Im Y, Wang R, Ma S. Partial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis. Life 2024, 14: 661. PMID: 38929645, PMCID: PMC11204969, DOI: 10.3390/life14060661.Peer-Reviewed Original ResearchOverall survivalHepatocellular carcinomaPartial hepatectomyTumor sizeAssociated with inferior overall survivalEarly-stage hepatocellular carcinomaEarly-stage HCC patientsInferior overall survivalHepatocellular carcinoma patientsAblation armCarcinoma patientsAblation therapyNo significant differenceTreatment regimensHCC patientsEmulated target trialSurgical proceduresEffect of ablationHepatectomyPatientsCompare treatment effectsClinical treatmentSignificant differencePropensity scoreLogistic regressionEffect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma.
Shewarega A, Santana J, Nam D, Berz A, Tefera J, Kahl V, Mishra S, Coman D, Duncan J, Roberts S, Wetter A, Madoff D, Chapiro J. Effect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma. Radiology 2024, 310: e232365. PMID: 38349244, PMCID: PMC10902598, DOI: 10.1148/radiol.232365.Peer-Reviewed Original ResearchConceptsT cell infiltrationCD8<sup>+</sup> T cellsMatrix metalloproteinase inhibitionT cellsHepatocellular carcinomaMatrix metalloproteinase inhibitorsMatrix metalloproteinasesResidual tumorCXCR3<sup>+</sup> CD8<sup>+</sup> T cellsCytotoxic CD8<sup>+</sup> T cell infiltrationIntratumoral CD8+ T cell infiltrationCD8+ T cell infiltrationCD8<sup>+</sup> T cell infiltrationMouse model of hepatocellular carcinomaEarly-stage hepatocellular carcinomaImage-guided tumor ablationUnpaired Student's <i>t</i> testModel of hepatocellular carcinomaFirst-line therapyMurine hepatocellular carcinomaT cell subsetsTumor-associated macrophagesMurine HCC modelLocal immune responseFemale BALB/c mice
2022
Pathogenesis to management of hepatocellular carcinoma
Da B, Suchman K, Lau L, Rabiee A, He A, Shetty K, Yu H, Wong L, Amdur R, Crawford J, Fox S, Grimaldi G, Shah P, Weinstein J, Bernstein D, Satapathy S, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes & Cancer 2022, 13: 72-87. PMID: 36533190, PMCID: PMC9746873, DOI: 10.18632/genesandcancer.226.Peer-Reviewed Original ResearchHepatocellular carcinomaCommon primary liver cancerEarly-stage hepatocellular carcinomaLiver-directed therapiesPathogenesis of HCCPrimary liver cancerMetastatic hepatocellular carcinomaViable animal modelAdvanced diseaseLiver resectionSystemic therapyPoor prognosisRisk factorsHCC managementHistological classificationLiver cancerNew therapiesAnimal modelsTherapyTissue samplingRelevant biomarkersAlcohol useMolecular targetsCarcinomaPathogenesisMachine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study.
Iseke S, Zeevi T, Kucukkaya AS, Raju R, Gross M, Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study. American Journal Of Roentgenology 2022, 220: 245-255. PMID: 35975886, PMCID: PMC10015590, DOI: 10.2214/ajr.22.28077.Peer-Reviewed Original ResearchConceptsEarly-stage hepatocellular carcinomaLiver transplantHepatocellular carcinomaImaging featuresPosttreatment recurrenceOrgan allocationMean AUCLiver transplant eligibilityPretreatment clinical characteristicsPretreatment MRI examinationsKaplan-Meier analysisKaplan-Meier curvesClinical characteristicsImaging surveillanceTherapy allocationTransplant eligibilityUnderwent treatmentClinical parametersRetrospective studyUnpredictable complicationMRI dataConcept studyPoor survivalClinical impactPretreatment MRIMR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features
Petukhova-Greenstein A, Zeevi T, Yang J, Chai N, DiDomenico P, Deng Y, Ciarleglio M, Haider SP, Onyiuke I, Malpani R, Lin M, Kucukkaya AS, Gottwald LA, Gebauer B, Revzin M, Onofrey J, Staib L, Gunabushanam G, Taddei T, Chapiro J. MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features. Journal Of Vascular And Interventional Radiology 2022, 33: 814-824.e3. PMID: 35460887, PMCID: PMC9335926, DOI: 10.1016/j.jvir.2022.04.006.Peer-Reviewed Original ResearchConceptsProgression-free survivalPoor progression-free survivalLiver Imaging ReportingHepatocellular carcinomaMR imaging biomarkersRadiomics signatureRadiofrequency ablationRadiomic featuresImaging biomarkersImaging ReportingFirst follow-up imagingMedian progression-free survivalRF ablationEarly-stage hepatocellular carcinomaPretreatment magnetic resonanceFirst-line treatmentMultifocal hepatocellular carcinomaSelection operator Cox regression modelTherapy-naïve patientsEarly-stage diseaseKaplan-Meier analysisCox regression modelLog-rank testFollow-up imagingPrediction of outcome
2021
Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2020
Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update
Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers 2020, 12: 791. PMID: 32224882, PMCID: PMC7226474, DOI: 10.3390/cancers12040791.Peer-Reviewed Original ResearchStage hepatocellular carcinomaSelective internal radiotherapyAdvanced-stage hepatocellular carcinomaTrans-arterial chemoembolizationHepatocellular carcinomaRecent large prospective trialsSimilar disease control rateManagement of HCCEarly-stage hepatocellular carcinomaStage of HCCDisease control rateSystemic treatment optionsLarge prospective trialsLocal disease controlCancer-related morbidityArterial therapyProspective trialImproved tolerabilityPalliative optionControl rateTreatment optionsTherapeutic strategiesDisease controlInternal radiotherapyTolerability
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply